MétaCan
Menu
Back to cohort

ACRIN 6695 perfusion CT as prognostic imaging biomarker in ovarian cancer.

2012· article· en· W2601151252 on OpenAlexaff
Chaan S. Ng, Ting Yim Lee, Robert L. Coleman, Zheng Zhang, Bernadine Dunning, Darryl Z. L’Heureux, Robert S. Mannel, Susanna I. Lee

Bibliographic record

VenueJournal of Clinical Oncology · 2012
Typearticle
Languageen
FieldMedicine
TopicMRI in cancer diagnosis
Canadian institutionsRobarts Clinical Trials
Fundersnot available
KeywordsMedicineCarboplatinResponse Evaluation Criteria in Solid TumorsOvarian cancerPerfusionPerfusion scanningChemotherapyOncologyInternal medicineRadiologyCancerPhases of clinical researchCisplatin

Abstract

fetched live from OpenAlex

TPS5114 Background: Tumor size and the cell surface glycoprotein CA125 levels have been traditional biomarkers for ovarian carcinoma, but remain suboptimal for assessing patients receiving chemotherapy. Current morphological criteria do not adequately evaluate lesion necrosis from anti-angiogenic therapy when no tumor volume change is measured. The evaluation of functional biomarkers rather than tumor volume may better distinguish responders from non-responders early in treatment with anti-angiogenic therapy. Perfusion CT can evaluate changes in tumor vascularity including blood flow (BF), blood volume (BV), mean transit time (MTT) and capillary permeability surface product (PS) before and after anti-angiogenic therapy with/out decrease in tumor volume. Objectives: The aims of the study are to evaluate the relationship between changes in tumor perfusion parameters and clinical outcomes of progression free survival, overall survival, and standard RECIST anatomic response criteria. A test-retest perfusion CT scan will also be performed to evaluate reproducibility of perfusion parameters in a subset of participants. Methods: In this collaborative trial, participants will be co-enrolled in the GOG-262 treatment trial. Participants will receive doublet chemotherapy of paclitaxel and carboplatin, followed by anti-angiogenic monoclonal therapy at cycle two. Perfusion CT will be performed at three time points: at baseline prior to therapy (T0), between days 18 and 21 of cycle one chemotherapy (T1), and at 8-10 days (T2) in anti-angiogenic monoclonal therapy. Participants with primary epithelial ovarian, peritoneal or fallopian tube cancer with optimally or suboptimally debulked FIGO Stage II, III or IV disease are eligible for the trial. Lesion eligibility will be evaluated by size and attenuation criteria. Accrual: ACRIN 6695 is activated at 12 GOG sites; 4/78 participants have accrued Discussion: Perfusion CT has been readily incorporated into the pre-existing clinical CT protocols and during scheduled RECIST scans. These perfusion CT functional maps of BF, BV, MTT and PS have been generated using vendor provided software without issue. Contact: Please contact Chaan Ng, MD cng@mdanderson.org for additional information.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.010

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.000
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.161
GPT teacher head0.527
Teacher spread0.366 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2012
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicMRI in cancer diagnosisFrench-language works237,207